Dada Now’s open platform for autonomous delivery honored at logistics summit

PR Newswire

  • Bing FU, General Manager of Dada Now shared insights on on-demand delivery at the Intra-City Logistics Summit 2022, held by the China Federation of Logistics & Purchasing (CFLP).
  • Since its launch in July 2021, Dada Now’s open platform for autonomous delivery has supported deliveries of over 50,000 supermarket orders.


NINGBO, China
, Sept. 30, 2022 /PRNewswire/ — With the volume of offline orders shrinking and more physical stores embracing an omni-channel strategy, intra-city retail has become a red-hot topic in the industry. Today, intra-city retail is catalyzing a new ecosystem, which is mainly characterized by the online-ization of supply chains and the digitization of retailers’ whole-chain operations, according to Bing FU, General Manager of Dada Now, the on-demand delivery arm of Dada Group (Nasdaq: DADA), at the CFLP Intra-City Logistics Summit 2022.

The boom in intra-city retail has been supported by intra-city delivery as the underlying infrastructure for fulfillment. Additionally, on-demand delivery and fulfillment capability has become a key determining factor in improving the consumer journey, increasing store capacity and growing intra-city retail coverage.

Three major trends in intra-city retail fulfillment decoded

At the summit, FU shared his thoughts on the development of intra-city fulfillment:

First, fulfillment is no longer simply limited to delivery. Fulfillment is more about the synergy of warehousing, order picking, packaging, package hand-over, delivery and after-sale service. Compared to the food delivery business, intra-city retail has a longer and much more complicated fulfillment chain, and requires highly robust and flexible delivery capacity during grand promotions. Hence, retailers need to improve the efficiency of each step in their daily operations to upgrade their fulfillment performance.

Second, as product categories and shopping scenarios present differentiated characteristics, merchants and consumers’ needs for fulfillment services are diversified. The delivery industry is rolling out customized fulfillment solutions for brands and merchants of different types and scales.

Third, the booming on-demand retail business in China allows consumers to place orders for almost anything (food and drinks, fresh and raw, consumer electronics, medications, etc.) from anywhere (home, office, hotel and more), driving the business scope of intra-city fulfillment to extend to all consumer groups, all regions, all categories, and all scenarios.

To address the retail industry’s expectations, Dada Now has rolled out a fulfillment service system that integrates its know-how in warehousing, order picking and delivery to help improve merchants’ fulfillment performance. The all-round fulfillment solution empowers retailers’ warehouse management, improves order picking efficiency, and accelerates deliveries.

Autonomous delivery practice praised

In July 2021, Dada Group launched an open platform dedicated to making autonomous delivery services smoother and smarter.

In collaboration with JD Logistics and unmanned vehicle developer White Rhino, the open platform for autonomous delivery operation is now deployed to merchant partners such as SEVEN FRESH, Sam’s Club, and Yonghui, to provide one-hour deliveries for consumers’ on-demand grocery orders. So far, over 50,000 orders have been processed though the autonomous delivery platform.

The platform proposes a smarter solution that helps lower costs, and improves efficiency for delivery partners, thanks to its three key functionalities, which are a smart dispatching system of unmanned vehicles, a human-vehicle interaction system, and a smart order management system. In addition to providing massive delivery orders, the platform also enables its partners with digitized operation tools, and a securer delivery experience.

For its efforts in driving forward the autonomous delivery, the platform was honored as an ‘Exemplary Case of Innovation’ at the summit.

Dada Now is committed to becoming a new infrastructure for intra-city retail, said FU at the event. “In the future, we will continue to give full play to our digital capabilities, empower the industry in every aspect of operation, and help partners with diverse needs to achieve the goal of ‘bringing people everything on demand’.”

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dada-nows-open-platform-for-autonomous-delivery-honored-at-logistics-summit-301637744.html

SOURCE DADA GROUP

Equifax Announces New Expedited Options for Manual Verifications of Income

PR Newswire

Priority Manual Verifications Help Expedite the Research Process for Financial Services and Government Customers


ATLANTA
, Sept. 30, 2022 /PRNewswire/ — Today, Equifax® (NYSE: EFX) announced enhancements to its manual verification of income (VOI) service from Equifax Workforce Solutions with Priority Next Day™ and Priority Two Day™ options, designed to help expedite the research process when information is not instantly available via The Work Number® database. As a result of these Priority enhancements, Equifax is further positioning itself as a resource of choice for customers to complete the verifications they need in support of quicker, more confident decisioning.

“Our customers rely on rapid verifications of income to help them meet the needs of consumers in today’s fast-paced world,” said Scott Maxfield, Vice President for Verifications at Equifax Workforce Solutions. “When instant verifications are not available, our manual Priority offerings provide a fast and convenient option, with built-in automation, to help move processes forward for social service determinations and redeterminations as well as for auto, credit, mortgage and personal loan decisions.”

Priority Next Day and Priority Two Day offerings deliver low-risk, high-value solutions by only charging customers for a completed Priority order. Customers may also use the hassle-free opt-in feature at order origination to automatically convert a Priority order to the Standard offering at Standard pricing if the order is not fulfilled within the designated Priority time frame. This comprehensive coverage ensures customers can obtain their verification answers in one convenient place.

Priority verifications complement the instant service provided by The Work Number, the industry-leading, centralized commercial source of income and employment information in the U.S. When information is not digitally available through The Work Number, Priority Next Day and Priority Two Day orders aim to fulfill the request by 11:59 p.m. Central time the next business day and the second business day, respectively.

Standard manual verifications are also still available for individual purchase. For more information on Priority verifications of income and other verification services available from Equifax Workforce Solutions, click here.

ABOUT EQUIFAX

At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by more than 13,000 employees worldwide, Equifax operates or has investments in 25 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.com

FOR MORE INFORMATION

Daniel Jenkins for Equifax Workforce Solutions
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/equifax-announces-new-expedited-options-for-manual-verifications-of-income-301637305.html

SOURCE Equifax Inc.

Uxin Reports Unaudited First Quarter of Fiscal Year 2023 Financial Results

BEIJING, Sept. 30, 2022 (GLOBE NEWSWIRE) — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), a leading e-commerce platform for buying and selling used cars in China, today announced its unaudited financial results for the first quarter ended June 30, 2022.


Highlights for the Quarter Ended June 30, 2022

  • Total revenues were RMB626.2 million (US$93.5 million) for the three months ended June 30, 2022, an increase of 23.8% from RMB505.7 million in the last quarter and an increase of 125.4% from RMB277.8 million in the same period last year.
  • Transaction volume was 5,475 units for the three months ended June 30, 2022, an increase of 29.4% from 4,231 units in the last quarter and an increase of 81.8% from 3,011 units in the same period last year.
  • Retail transaction volume was 2,407 units, an increase of 30.2% from 1,848 units in the last quarter and an increase of 254.5% from 679 units in the same period last year.
  • Gross margin was 1.1% for the three months ended June 30, 2022, compared with 0.2% in the last quarter and 4.0% in the same period last year.
  • Loss from operations was RMB96.6 million (US$14.4 million) for the three months ended June 30, 2022, compared with RMB109.5 million in the last quarter and RMB50.7 million in the same period last year.
  • Non-GAAP adjusted loss from operations was RMB84.9 million (US$12.7 million) for the three months ended June 30, 2022, compared with RMB96.1 million in the last quarter and RMB44.6 million in the same period last year.

Mr. Kun Dai, Founder, Chairman and Chief Executive Officer of Uxin, commented, “We maintained our growth momentum during this quarter as our retail transaction volume increased by 30.2% quarter over quarter and 254.5% year over year to 2,407 units. In Xi’an and Hefei, where our two IRCs are located, our regional market share leadership continued to expand. At the same time, our NPS remained at an industry leading level of 60 in the quarter, testifying the broad acknowledgement of our high quality used car offerings and services. To further improve our customers’ shopping experience, we launched the National Standard Vehicle Dashboard for our customers to understand the vehicle conditions more intuitively and make purchasing decision more efficiently. Additionally, as we continued to optimize business processes, we have significantly reduced our vehicles’ reconditioning time and retail turnover days compared to a year ago.”

Mr. Dai continued, “The Ministry of Commerce, together with 16 other relevant departments, had been implementing a series of business- and tax-oriented supportive policies to boost the used car industry in China, most of which will become effective on October 1, 2022. Well-branded, large-scale, and compliant used car companies like Uxin will benefit greatly from these policies. As the leader in China’s used car e-commerce business, we are well-positioned to sustain our high-quality growth on the back of the industry tailwind.”

Mr. John Lin, Chief Financial Officer of Uxin, said: “Our total revenue for the first fiscal quarter reached RMB626.2 million, growing 23.8% quarter over quarter and 125.4% year over year. In particular, our retail revenue in the quarter increased by 9.1% quarter over quarter and 279.7% year over year to RMB348.4 million. Driven by inventory optimization, our gross profit margin started to recover and is expected to continue growing in the following quarters. Additionally, we further strengthened our balance sheet by completing the issuance of Class A ordinary shares to ClearVue at a price of $1.03 per ADS in exchange for fully releasing the Company’s obligations under the convertible promissory note with an aggregated principal amount of USD$12.6 million.” 


Financial Results for the Quarter Ended June 30, 2022


Total revenues were RMB626.2 million (US$93.5 million) for the three months ended June 30, 2022, an increase of 23.8% from RMB505.7 million in the last quarter and an increase of 125.4% from RMB277.8 million in the same period last year. The increases were driven by the growth of total transaction volume.


Retail vehicle sales revenue
was RMB348.4 million(US$52.0 million) for the three months ended June 30, 2022, representing an increase of 9.1% from RMB319.3 million in the last quarter and an increase of 279.7% from RMB91.7 million in the same period last year. For the three months ended June 30, 2022, retail transaction volume was 2,407 units, an increase of 30.2% from 1,848 units last quarter and an increase of 254.5% from 679 units in the same period last year. The increases were driven by the growth of retail transaction volume as the Company’s Hefei IRC maintained its steady growth while its Xi’an IRC continued to recover from COVID-induced disruptions. The increases were partially offset by slight decreases in average selling prices as the Company started shifting its focus towards mid-range priced vehicles. The increased sales volume of mid-range priced vehicles and the promotion programs the Company launched to boost the sales of its higher priced vehicles led to a lower average selling price in the quarter.


Wholesale vehicle sales revenue
was RMB264.0 million (US$39.4 million) for the three months ended June 30, 2022, compared with RMB179.7 million in the last quarter and RMB176.6 million in the same period last year. For the three months ended June 30, 2022, wholesale transaction volume was 3,068 units, representing an increase of 28.7% from 2,383 units last quarter and an increase of 31.6% from 2,332 units in the same period last year. Wholesale vehicle sales refers to the vehicles the Company purchased from individuals but did not meet the Company’s retail standards thus were wholesaled through online and offline channels. With the gradual recovery from the COVID-19 resurgence in last quarter, the Company purchased more vehicles from individuals in this quarter, resulting in more wholesale vehicle sales.


Other revenue
was RMB13.8 million (US$2.1 million) for the three months ended June 30, 2022, compared with RMB6.8 million in the last quarter and RMB9.5 million in the same period last year.

Cost of revenues was RMB619.4 million (US$92.5 million) for the three months ended June 30, 2022, compared with RMB504.6 million in the last quarter and RMB266.7 million in the same period last year.

Gross margin was 1.1% for the three months ended June 30, 2022, compared with 0.2% in the last quarter and 4.0% in the same period last year. In order to better meet the changes in customers’ preference and improve the inventory turnover, the Company has been continuously optimizing its inventory structure, and started to shift its focus towards mid-range priced vehicles. The increased sales volume of mid-ranged priced vehicles and the promotion programs the Company launched to boost the sales of its higher priced vehicles led to a lower average selling price in the quarter. In addition, the Company started writing down the higher priced vehicles in its inventory that were unsold since last quarter, leading to the decrease of gross margin compared with the same period of last year.

Total operating expenses were RMB119.0 million (US$17.8 million) for the three months ended June 30, 2022. Total operating expenses excluding the impact of share-based compensation were RMB107.3 million.


  • Sales and marketing expenses
    were RMB64.8 million (US$9.7 million) for the three months ended June 30, 2022, compared with RMB67.8 million in the last quarter and an increase of 53.7% from RMB42.2 million in the same period last year. The year-over-year increase was mainly due to increases in performance incentives for the sales teams and vehicle transaction costs as a result of higher transaction volume. In addition, the Company also recorded increased brand promotion expenses in Xi’an and Hefei where the Company’s IRCs are located. Share-based compensation expenses associated with sales and marketing expenses were nil during the quarter. 

  • General and administrative expenses
    were RMB45.6 million (US$6.8 million) for the three months ended June 30, 2022, representing an increase of 11.8% from RMB40.7 million in the last quarter and an increase of 18.8% from RMB38.3 million in the same period last year. The quarter-over-quarter increase was mainly due to the increase of professional fees. The year-over-year increase was mainly due to the impact of share-based compensation. General and administrative expenses excluding the impact of share-based compensation were RMB33.9 million. 

  • Research and development expenses
    were RMB9.0 million (US$1.3 million) for the three months ended June 30, 2022, representing an increase of 6.2% from RMB8.4 million in the last quarter and an increase of 7.5% from RMB8.3 million in the same period last year. Share-based compensation expenses associated with research and development expenses were nil during the quarter.

Loss from operations was RMB96.6 million (US$14.4 million) in the three months ended June 30, 2022, compared with RMB109.5 million for the last quarter and RMB50.7 million in the same period last year.

Non-GAAP adjusted loss from operations which excludes the impact of share-based compensation was RMB84.9 million (US$12.7 million) in the three months ended June 30, 2022, compared with RMB96.1 million in the last quarter and RMB44.6 million for the same period last year.

Fair value impact related to the senior convertible preferred shares resulted in a gain of RMB252.2 million (US$37.7 million) for the three months ended June 30, 2022, compared with a gain of RMB476.8 million in the last quarter. The impact was mainly due to the fair value change of the warrants and forward contracts issued in connection with the senior convertible preferred shares during the period. The fair value impact was a non-cash gain.

Net income/ (loss) from operations was net income of RMB160.0 million (US$23.9 million) for the three months ended June 30, 2022, compared with net income of RMB360.8 million for the last quarter and net loss of RMB69.2 million for the same period last year.

Non-GAAP adjusted net loss from operations was RMB80.5 million (US$12.0 million) for the three months ended June 30, 2022, compared with RMB102.6 million in the last quarter and RMB63.1 million in the same period last year.


Liquidity


As of June 30, 2022, the Company had RMB88.2 million (US$13.2 million) in cash and cash equivalents. The cash and cash equivalents primarily consist of cash on hand and deposits placed with financial institutions that can be added to or withdrawn without limitation. The Company has been incurring losses from operations since the inception. The Company incurred loss from operations of RMB96.6 million (US$14.4 million) in three months ended June 30, 2022. Net current liabilities amounted to RMB265.3 million (US$39.6 million) as of June 30, 2022.

The Company is entitled to receive a total amount of investment of US$100 million from NIO Capital for the senior convertible preferred shares, payable in multiple installments due before June 2023. The Company also issued Class A ordinary shares to 58.com Holdings Inc. (“58.com”) and ClearVue UXin Holdings, Ltd. (“ClearVue”) in exchange for the full release of the Company’s obligations under the previously issued convertible notes which was further modified in July 2021. Concurrently, in order to settle a long-term borrowing, the Company entered into a loan agreement (which pledges an equity interest in an investment) for a total of RMB290 million with a third party. Meanwhile, the Company continues to optimize the cost and expense structure to improve the capital and operating efficiency of the business process. Considering all the actions mentioned above, which have alleviated the substantial doubt of its ability to continue as a going concern, the Company believes that its current cash and cash equivalents, and cash proceeds received (or to be received) from the recent financing transactions will be sufficient to meet its anticipated working capital requirements and maturing debt obligations within the next twelve months of operations.

Additionally, the Company has consideration payable to WeBank and long-term debt that will become due after the next twelve months of operations upon this earning release date. These obligations, the rental commitment post completion of Hefei IRC and the likelihood that the Company will continue to incur net losses and negative operating cash flows will impact its liquidity. Concurrently, as part of the shares subscription agreement the Company entered into with NIO Capital and Joy Capital (the “Investors”) in June 2021, the Investors retain their rights to exercise the warrants to purchase senior convertible preferred shares of up to US$165 million. Management’s plan to sustain sufficient liquidity despite the existence of these obligations and ongoing working capital needs includes: (i) negotiating with the Investors to exercise their warrants; and (ii) restructuring existing obligations to reduce cash payments; and (iii) working on several other initiatives to further improve its working capital efficiency.


Recent Development


On August 29, 2022, the Company announced that it has issued 36,699,029 Class A ordinary shares, par value US$0.0001 per share, of the Company (equivalent to approximately 12,233,010 American Depositary Shares (“ADSs”)) to ClearVue UXin Holdings, Ltd. (“ClearVue”) in exchange for the full release of the Company’s obligations under the convertible promissory note issued to ClearVue on June 10, 2019 (such note, as amended, the “ClearVue Note”) in an aggregate principal amount of US$12.6 million. These shares were issued at a price equivalent to US$1.03 per ADS. The ClearVue Note was extinguished upon such issuance of shares.


Business Outlook


For the three months ending September 30, 2022, the Company expects its retail transaction volume to be around 3,000 units, representing an increase of 25% quarter over quarter and an increase of 192% year over year. The average selling price (ASP) for retailed cars is expected to be around RMB119,000. The Company also expects its wholesale transaction volume to be around 2,800 units with ASP expected to be around RMB82,000. The Company estimates that its total revenues including retail vehicle sales revenue, wholesale vehicle sales revenue and value-add-services revenue to be in the range of RMB590 million to RMB610 million. These forecasts reflect our current and preliminary views on the market and operational conditions, which are subject to changes.


Conference Call


The Company’s management will host an earnings conference call on September 30, 2022 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong time on the same day).

Due to the outbreak of COVID-19, operator assisted conference calls are not available at the moment. All participants must preregister online prior to the call to receive the dial-in details.

Conference Call Preregistration

Participants can register for the conference call by navigating to https://s1.c-conf.com/DiamondPass/10025601-fr75uh.html. Once preregistration has been completed, participants will receive dial-in numbers, an event passcode, and a unique registrant ID.

To join the conference, please dial the number you receive, enter the event passcode followed by your unique registrant ID, and you will be joined to the conference instantly.

A telephone replay of the call will be available after the conclusion of the conference call until October 7, 2022. The dial-in details for the replay are as follows:

U.S.: +1 855 883 1031
China: +86 400 1209 216
Replay PIN: 10025601

A live webcast and archive of the conference call will be available on the Investor Relations section of Uxin’s website at http://ir.xin.com.

About Uxin

Uxin Limited (Nasdaq:UXIN) is a leading e-commerce platform for buying and selling used cars in China. We offer high-quality and value-for-money vehicles as well as superior after-sales services through a reliable, one-stop, and hassle-free transaction experience. Under our omni-channel strategy, we are able to leverage our pioneering online platform to serve customers nationwide and establish market leadership in selected regions through offline inspection and reconditioning centers. Leveraging our extensive industry data and continuous technology innovation throughout more than ten years of operation, we have established strong used car management and operation capabilities. We are committed to upholding our customer-centric approach and driving the healthy development of the used car industry.

Use of Non-GAAP Financial Measures

In evaluating the business, the Company considers and uses certain non-GAAP measures, including adjusted loss from continuing operations and adjusted net loss from continuing operations and adjusted net loss from continuing operations per share – basic and diluted, as supplemental measures to review and assess its operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. The Company defines adjusted loss from continuing operations as loss from continuing operations excluding share-based compensation. The Company defines adjusted net loss from continuing operations as net loss from continuing operations excluding the impact of share-based compensation and the fair value impact of the issuance of senior convertible preferred shares, including the troubled debt restructuring gain. The Company defines adjusted net loss from continuing operations per share – basic and diluted as net loss from continuing operations per share excluding the impact of share-based compensation and the fair value impact of the issuance of senior convertible preferred shares, including the troubled debt restructuring gain. The Company presents the non-GAAP financial measure because it is used by the management to evaluate its operating performance and to formulate business plans. Adjusted net loss from continuing operations enables management to assess the Company’s operating results without considering the impact of share-based compensation and fair value impact of the issuance of senior convertible preferred shares, including the troubled debt restructuring gain, which are non-cash charge or credits. The Company also believes that the use of the non-GAAP measure facilitates investors’ assessment of its operating performance as this measure excludes certain expenses that are not expected to result in cash payments.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using adjusted net loss from continuing operations is that it does not reflect all items of income and expense that affect the Company’s operations. Share-based compensation and the fair value impact of the issuance of senior convertible preferred shares have been and may continue to be incurred in the business and are not reflected in the presentation of adjusted net loss from continuing operations, and adjusted net loss from continuing operations per share – basic and diluted. Further, non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.

The Company compensates for these limitations by reconciling the non-GAAP financial measure to the nearest U.S. GAAP performance measure, all of which should be considered when evaluating the Company’s performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliations of Uxin’s non-GAAP financial measures to the most comparable U.S. GAAP measure are included at the end of this press release.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader, except for those transaction amounts that were actually settled in U.S. dollars. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB6.6981 to US$1.00, representing the index rate as of June 30, 2022 set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as Uxin’s strategic and operational plans, contain forward-looking statements. Uxin may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Uxin’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: impact of the COVID-19 pandemic, Uxin’s goal and strategies; its expansion plans; its future business development, financial condition and results of operations; Uxin’s expectations regarding demand for, and market acceptance of, its services; its ability to provide differentiated and superior customer experience, maintain and enhance customer trust in its platform, and assess and mitigate various risks, including credit; its expectations regarding maintaining and expanding its relationships with business partners, including financing partners; trends and competition in China’s used car e-commerce industry; the laws and regulations relating to Uxin’s industry; the general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Uxin’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Uxin does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media enquiries, please contact:

Uxin Limited Investor Relations

Ms. Joyce Tang
Phone: +86 10 5691-6765
Email: [email protected] 

The Blueshirt Group

Jack Wang
Phone: +86 166-0115-0429
Email: [email protected]

 

Uxin Limited  
Unaudited Consolidated Statements of Comprehensive Loss  
(In thousands except for number of shares and per share data)  
               
    For the three months ended June 30,  
    2021
  2022
 
    RMB   RMB   US$  
Revenues              
Retail vehicle sales   91,745     348,393     52,014    
Wholesale vehicle sales   176,591     263,956     39,408    
Others   9,482     13,821     2,063    
Total revenues   277,818     626,170     93,485    
               
Cost of revenues   (266,689 )   (619,411 )   (92,476 )  
Gross profit   11,129     6,759     1,009    
               
Operating expenses              
Sales and marketing   (42,159 )   (64,798 )   (9,674 )  
General and administrative   (38,347 )   (45,575 )   (6,804 )  
Research and development   (8,338 )   (8,960 )   (1,338 )  
Reversal of credit losses, net   5,476     377     56    
Total operating expenses   (83,368 )   (118,956 )   (17,760 )  
               
Other operating income, net   21,542     15,580     2,326    
               
Loss from operations   (50,697 )   (96,617 )   (14,425 )  
               
Interest income   3,045     270     40    
Interest expenses   (18,389 )   (5,448 )   (813 )  
Other income   1,114     14,249     2,127    
Other expenses   (818 )   (1,727 )   (258 )  
Foreign exchange losses   (3,723 )   (2,748 )   (410 )  
Fair value impact of the issuance of senior convertible preferred shares (i)       252,190     37,651    
(Loss)/income before income tax expense   (69,468 )   160,169     23,912    
Income tax expense       (151 )   (23 )  
Equity in income/ (losses) of affiliates   276     (38 )   (6 )  
Net (loss)/income, net of tax   (69,192 )   159,980     23,883    
Less: net loss attributable to non-controlling interests shareholders       (3 )      
Net (loss)/income attributable to UXIN LIMITED’s ordinary shareholders   (69,192 )   159,983     23,883    
               
Net (loss)/income   (69,192 )   159,980     23,883    
Foreign currency translation, net of tax nil   24,870     (58,660 )   (8,758 )  
               
Total comprehensive (loss)/income   (44,322 )   101,320     15,125    
Less: total comprehensive loss attributable to non-controlling interests shareholders       (3 )      
Total comprehensive (loss)/income attributable to UXIN LIMITED’s ordinary shareholders   (44,322 )   101,323     15,125    
               
Net (loss)/income attributable to UXIN LIMITED’s ordinary shareholders   (69,192 )   159,983     23,883    
Weighted average shares outstanding – basic   1,116,946,693     1,189,841,431     1,189,841,431    
Weighted average shares outstanding – diluted   1,116,946,693     1,193,043,619     1,193,043,619    
               
Net (Loss)/income per share for ordinary shareholders, basic   (0.06 )   0.09     0.01    
Net (Loss)/income per share for ordinary shareholders, diluted   (0.06 )   0.09     0.01    
               
(i) In June 2021, we entered into a share subscription agreement with NIO Capital and Joy Capital, respectively, for an aggregate investment amount of up to US$315 million for the subscription of senior convertible preferred shares. The first closing in the amount of US$100 million was completed for the issuance of 291,290,416 senior convertible preferred shares on July 12, 2021. On the same day, we also issued warrants to each of NIO Capital and Joy Capital to purchase up to 240,314,593 senior convertible preferred shares for an aggregate amount of US$165 million which was included in the aforementioned US$315 million. The second closing in the amount of US$50 million is expected to be received subject to customary closing conditions, out of which US$27.5 million,US$10 million and US$7.5 million were received in November 2021, in March and June 2022, respectively. For the remaining US$5 million, on July 27, 2022, NIO Capital assigned its rights and obligations to an independent third party, from whom we received this remaining US$5 million. According to U.S. GAAP, all proceeds received in the first closing was allocated to warrants. Warrants and the second closing contract are recorded as warrant liabilities and forward contract liabilities or assets at fair value respectively with subsequent fair value change to be charged into the profit and loss. Total fair value impact during the reported quarter was RMB252.2 million (US$37.7 million).  

Uxin Limited
Unaudited Consolidated Balance Sheets
(In thousands except for number of shares and per share data)
             
    As of March 31,   As of June 30,
    2022   2022
  RMB   RMB   US$
ASSETS            
Current assets            
Cash and cash equivalents   128,021     88,189     13,166  
Restricted cash   8,276     4,691     700  
Accounts receivable, net   832     1,386     210  
Loans recognized as a result of payments under guarantees, net of provision for credit losses of RMB324,371 and RMB323,190 as of March 31, 2022 and June 30, 2022, respectively   54,888     50,599     7,554  
Other receivables, net of provision for credit losses of RMB30,251 and RMB29,581 as of March 31, 2022 and June 30, 2022, respectively   166,006     164,808     24,605  
Inventory, net   426,257     378,889     56,567  
Forward contract assets (i)   36     19,640     2,932  
Prepaid expenses and other current assets   90,012     63,010     9,407  
Total current assets   874,328     771,212     115,141  
             
Non-current assets            
Property, equipment and software, net   34,531     36,097     5,389  
Long term investments   288,756     288,718     43,104  
Other non-current assets (ii)   24,000     21,000     3,135  
Right-of-use assets, net   29,584     24,590     3,671  
Total non-current assets   376,871     370,405     55,299  
             
Total assets   1,251,199     1,141,617     170,440  
             
LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT            
Current liabilities            
Accounts payable   92,534     83,821     12,514  
Guarantee liabilities   179     111     17  
Warrant liabilities (i)   196,390     416     62  
Other payables and other current liabilities (iii)   674,333     611,097     91,235  
Current portion of long-term borrowings   233,000     233,000     34,786  
Current portion of long-term debt (iv)   102,206     108,054     16,132  
Total current liabilities   1,298,642     1,036,499     154,746  
             
Non-current liabilities            
Consideration payable to WeBank (v)   107,642     79,041     11,801  
Operating lease liabilities   10,866     11,003     1,643  
Long-term debt (iv)   817,648     864,428     129,056  
Total non-current liabilities   936,156     954,472     142,500  
             
Total liabilities   2,234,798     1,990,971     297,246  
             
Mezzanine equity            
Senior convertible preferred shares (US$0.0001 par value, 1,000,000,000 shares authorized as of March 31, 2022 and June 30, 2022, respectively; 400,524,323 and 422,371,104 shares issued and outstanding as of March 31, 2022 and June 30, 2022, respectively) (i)   526,484     547,719     81,772  
Total Mezzanine equity   526,484     547,719     81,772  
             
Shareholders’ deficit            
Ordinary shares   782     782     117  
Additional paid-in capital   14,254,109     14,265,799     2,129,828  
Accumulated other comprehensive income   288,461     229,801     34,308  
Accumulated deficit   (16,053,272 )   (15,893,289 )   (2,372,806 )
Total Uxin’s shareholders’ deficit   (1,509,920 )   (1,396,907 )   (208,553 )
Non-controlling interests   (163 )   (166 )   (25 )
Total shareholders’ deficit   (1,510,083 )   (1,397,073 )   (208,578 )
             
Total liabilities, mezzanine equity and shareholders’ deficit   1,251,199     1,141,617     170,440  
             
(i) In June 2021, we entered into a share subscription agreement, respectively, with NIO Capital and Joy Capital for an aggregate investment amount of up to US$315 million for the subscription of senior convertible preferred shares. The first closing in the amount of US$ 100 million was completed for the issuance of 291,290,416 senior convertible preferred shares on July 12, 2021. On the same day, we also issued warrants to each of NIO Capital and Joy Capital to purchase up to 240,314,593 senior convertible preferred shares for an aggregate amount of US$165 million which was included in the aforementioned US$315 million. According to U.S. GAAP, all proceeds received in the first closing was allocated to warrants. Warrants and the second closing contract are recorded as warrant liabilities and forward liabilities, respectively, with subsequent fair value change to be charged into the profit and loss.

The second closing in the amount of US$50 million is expected to be received subject to customary closing conditions, out of which US$27.5 million , US$10 million and US$7.5 million were received in November 2021, March and June 2022, respectively, For the remaining US$5 million, on July 27, 2022, NIO Capital assigned its rights and obligations to an independent third party, from whom we received this remaining US$5 million. The corresponding fair value was transferred from forward contract liabilities to mezzanine equity on the same day.

(ii) Other non-current assets represented our prepayment for financial solution advisory services. We entered into a long-term strategic cooperation agreement with Golden Pacer separately in April 2020, and an aggregate amount of RMB60.0 million as prepayment was made in exchange for a 5-year financial solution advisory services from Golden Pacer.

(iii) Pursuant to a contractual payment schedule contained in a supplemental agreement signed with one of our suppliers, in order to settle all payables due to this supplier, a total of RMB56.1 million will be waived after full payment is made by us as long as we make payments on schedule. As of June 30, 2022, a total of RMB105.2 million was recorded and the last payment will be made by December 2022. Currently, we made the payments on schedule.

(iv) In June 2021, we entered into a supplemental agreement with affiliates of 58.com, Warburg Pincus, TPG and certain other investors who held a total of US$230.0 million convertible notes (“2024 Notes”). Pursuant to the supplemental agreement, 30% of the outstanding 2024 Notes principal amount will be converted into a total of 66,990,291 Class A ordinary shares at a price of US$1.03 per Class A ordinary share upon the first closing. On July 12, 2021, aforementioned conversion was completed and related Class A ordinary shares were issued. Remaining principal amount will be repaid by instalments by us from July 2021 to June 2024 and recorded as current portion of long-term debt and long-term debt. Besides, interest term was modified and 2024 Notes bear no interest from the original issuance date.

(v) On July 23, 2020, we entered into a supplemental agreement with WeBank to settle our remaining guarantee liabilities associated with the historically-facilitated loans for WeBank. Pursuant to the supplemental agreement, we will pay an aggregate amount of RMB372 million to WeBank from 2020 to 2025 as guarantee settlement with a maximum annual settlement amount of no more than RMB84 million. Upon the signing of the supplemental agreement, we are also no longer subject to guarantee obligations in relation to our historically-facilitated loans for WeBank under the condition that we make the instalment payments based on the agreed-upon schedule set forth in the supplemental agreement.

On June 21, 2021, we entered into another supplemental agreement with WeBank and under this supplemental agreement a total of RMB48 million instalment payments will be waived (represents present value of RMB42.2 million) immediately upon the effectiveness of this supplemental agreement. The effectiveness of this supplemental agreement is conditioned on the closing of the first tranche of financing with NIO Capital and Joy Capital. The first tranche of financing closed on July 12, 2021 and therefore this supplemental agreement became effective on July 12, 2021, and related waived payment was recorded in other operating income. As of June 30, 2022, total outstanding payables was RMB132.8 million, out of which RMB53.8 million was recorded in “consideration payable to WeBank” and the remaining was recorded in “other payables and other current liabilities”.

* Share-based compensation charges are as follows:            
             
    For the three months ended June 30,
    2021   2022
    RMB   RMB   US$
Cost of revenues      
Sales and marketing      
General and administrative   6,142   11,690   1,745
Research and development      

Uxin Limited  
Unaudited Reconciliations of GAAP And Non-GAAP Results  
(In thousands except for number of shares and per share data)  
               
               
    For the three months ended June 30,  
    2021
  2022
 
    RMB   RMB   US$  
Loss from operations   (50,697 )   (96,617 )   (14,425 )  
Add: Share-based compensation expenses   6,142     11,690     1,745    
– Cost of revenues              
– Sales and marketing              
– General and administrative   6,142     11,690     1,745    
– Research and development              
               
Non-GAAP adjusted loss from operations   (44,555 )   (84,927 )   (12,680 )  
               
    For the three months ended June 30,  
    2021
  2022
 
    RMB   RMB   US$  
Net (loss)/ income from operations   (69,192 )   159,980     23,883    
               
Add: Share-based compensation expenses   6,142     11,690     1,745    
– Cost of revenues              
– Sales and marketing              
– General and administrative   6,142     11,690     1,745    
– Research and development              
Fair value impact of the issuance of senior convertible preferred shares       (252,190 )   (37,651 )  
               
Non-GAAP adjusted net loss from operations   (63,050 )   (80,520 )   (12,023 )  
               
Net (loss)/income from operations per share – basic   (0.06 )   0.09     0.01    
Net (loss)/income from operations per share – diluted   (0.06 )   0.09     0.01    
Non-GAAP adjusted net loss from operations per share – basic   (0.06 )   (0.07 )   (0.01 )  
Non-GAAP adjusted net loss from operations per share – diluted   (0.06 )   (0.07 )   (0.01 )  
Weighted average shares outstanding – basic   1,116,946,693     1,189,841,431     1,189,841,431    
Weighted average shares outstanding – diluted   1,116,946,693     1,193,043,619     1,193,043,619    
               
Note: The conversion of Renminbi (RMB) into U.S. dollars (USD) is based on the certified exchange rate of USD1.00 = RMB6.6981 as of June 30, 2022 set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System.  

  



BiondVax announces financial plans to support its ongoing NanoAb pipeline development

PR Newswire


JERUSALEM, Israel 
, Sept. 30, 2022 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced the filing yesterday of a Registration Statement (“Form F-1”) with the US Securities and Exchange Commission (“SEC”) for a firm commitment underwritten offering of BiondVax American Depositary Shares (“ADSs”). Once declared effective by the SEC the Form F-1 can be used to raise capital.

BiondVax Logo

BiondVax is currently developing, under an exclusive worldwide license, a nanosized antibody (“NanoAb”) for the treatment of COVID-19, developed by researchers at the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG). As recently reported, in the coming weeks BiondVax intends to initiate a preclinical proof-of-concept study of the COVID-19 NanoAb as an inhaled therapy in COVID-19 infected animals. Assuming successful results, a first-in-human Phase 1/2a clinical trial of the COVID-19 NanoAb inhaled therapy will be initiated in 2023.

Under the five-year BiondVax-MPG-UMG research collaboration agreement (RCA) for additional “biobetter” NanoAbs, Professor Dirk Görlich of MPG and his team have successfully generated, identified and isolated NanoAbs addressing a number of additional biological target molecules. Professor Görlich and his colleague Professor Matthias Dobbelstein of UMG verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. The research teams have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. As a result of the above progress, BiondVax decided earlier this month to initially focus additional pipeline development beginning with NanoAbs as drug candidates for the potential treatment of psoriasis, psoriatic arthritis, and asthma.

These recent successful developments present BiondVax with an opportunity to not only initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb next year as planned, but also to significantly expand its portfolio of NanoAbs in development. Consequently, the proceeds of the firm commitment underwriting share issuance contemplated by the F-1 are designed to provide BiondVax with the capital necessary to continue to aggressively execute its strategy.

In addition, BiondVax received a notification letter from The Nasdaq Stock Market (“Nasdaq”) dated September 28, 2022 advising BiondVax that it is not in compliance with Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The notification letter from Nasdaq was based on BiondVax’s Form 6-K/A, dated August 29, 2022, disclosing financial information for the period ended June 30, 2022, which reported shareholders’ equity of $1,277,000, and noted that BiondVax does not meet the alternatives of market value of listed securities or net income from continued operations.

The letter states that under Nasdaq’s Listing Rules, BiondVax has 45 calendar days to submit a plan to Nasdaq to regain compliance with the minimum stockholders’ equity listing requirement. If a plan is submitted by BiondVax, and if it is accepted by Nasdaq, Nasdaq can grant an extension of up to 180 days from the date of the Nasdaq letter for BiondVax to evidence compliance with the minimum stockholders’ equity listing requirement. If BiondVax submits a plan and the plan is not accepted by Nasdaq, BiondVax will have the opportunity to appeal such decision to a Nasdaq Hearings Panel under Nasdaq Listing Rule 5815(a).

The notification letter has no immediate effect on the listing of BiondVax’s ADSs, and its ADSs will continue at this time to trade on the Nasdaq Capital Market under the symbol “BVXV”.

The contemplated equity offering, if consummated, would rectify the stockholders’ equity deficiency. Furthermore, BiondVax will pursue additional definitive steps to regain and maintain compliance with Nasdaq listing rules.


Amir Reichman
, BiondVax’s CEO, explained, “As we updated last week, in addition to the upcoming COVID–19 NanoAb milestones, following exciting progress made by our scientific collaborators at the Max Planck Institute for Multidisciplinary Sciences (MPG), and the University Medical Center Göttingen (UMG) we intend to advance development of additional NanoAbs for the treatment of diseases such as asthma, psoriatic arthritis and psoriasis. While the stock market remains unfavorable, particularly for small cap companies, we believe aggressively advancing our programs is the best path to create shareholder value to be reflected when the market regains some stability. We view the registration statement filed yesterday for a proposed equity offering as one piece of a well-crafted set of activities to ensure BiondVax continues to deliver. While the decision to pursue an offering was made in advance of the letter of non-compliance, we are optimistic that the offering’s successful conclusion will address the deficiency and put the issue behind us. To be prudent we will pursue additional measures in parallel, consistent with our proactive approach to restructuring our loan from the European Investment Bank, as previously announced.”

About BiondVax

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. www.biondvax.com.

Contact Details

Company: Joshua E. Phillipson | +972 8 930 2529 | [email protected]

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financings, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, the therapeutic and commercial potential of nanosized antibodies (NanoAbs); and the timing of NanoAb proof-of-concept studies and clinical trials. These forward-looking statements reflect management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that the company may not raise capital on acceptable terms or at all, the risk that the company will not submit a compliance plan acceptable to Nasdaq, the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities; BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo – https://mma.prnewswire.com/media/615570/BiondVax_Pharmaceuticals_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/biondvax-announces-financial-plans-to-support-its-ongoing-nanoab-pipeline-development-301637726.html

SOURCE Biondvax Pharmaceuticals Ltd

First High-School Education Group Announces Declaration of a Dividend

PR Newswire


BEIJING
, Sept. 30, 2022 /PRNewswire/ — First High-School Education Group Co., Ltd. (“First High-School Education Group” or the “Company”) (NYSE: FHS), an education service provider primarily focusing on high schools in Western China, today announced that its board of directors (the “Board”) has approved and declared a cash dividend of US$0.0146 per ordinary share (US$0.0437 per American depositary share, or ADS).

The amount of cash dividends to be distributed is approximately US$1.24 million in total, net of 10.0% withholding tax. The dividends are expected to be paid on October 18, 2022 to the holders of the Company’s ordinary shares (including those represented by the ADSs) of record as of the close of business on October 11, 2022. The determination to declare and pay the dividend and the amount of dividend in any year will be made at the discretion of the Board and will be based upon the Company’s operations and earnings, cash flow, financial condition and other relevant factors that the Board may deem appropriate.

About First High-School Education Group

First High-School Education Group is an education service provider primarily focusing on high schools in Western China. The Company aspires to become a leader and innovator of private high school education in China, with the focuses on a comprehensive education management integrating education information consulting, education research project development, education talent management, education technology management, education service management, and general vocational integration development services. For more information, please visit https://ir.diyi.top/.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For Investor and Media Inquiries Please Contact:

First High-School Education Group
Tommy Zhou
Chief Financial Officer
E-mail: [email protected] 

Customer Service
E-mail: [email protected]
Phone: 010-62555966 (9:30-12:00, 13:30-16:00 CST)

Cision View original content:https://www.prnewswire.com/news-releases/first-high-school-education-group-announces-declaration-of-a-dividend-301637551.html

SOURCE First High-School Education Group Co., Ltd

American Outdoor Brands Board of Directors Approves $10 Million Share Repurchase Program

PR Newswire


COLUMBIA, Mo.
, Sept. 30, 2022 /PRNewswire/ — American Outdoor Brands, Inc. (NASDAQ Global Select: AOUT), an industry leading provider of products and accessories for outdoor enthusiasts, today announced that its Board of Directors has approved the repurchase of up to $10 million of the Company’s outstanding common stock (“shares”) through September 2023. The share repurchase program is effective immediately.

President and Chief Executive Officer, Brian Murphy, said, “This announcement underscores our Board’s confidence in our business and its dedication to stockholder value creation. Our strong balance sheet and anticipated positive cash flow enable us to prioritize investing for growth, both organically and through opportunistic and accretive M&A activity, while maintaining our commitment to returning capital to our stockholders. As we evaluate our capital allocation priorities, we believe it is appropriate and important to have the authority to repurchase stock at our discretion.”

The shares may be repurchased from time to time on the open market, in block trades, or in privately negotiated transactions. The amount and timing of any shares repurchased under the program will be determined at the discretion of management and will depend on a number of factors, including the market price of the company’s stock, trading volume, general market and economic conditions, the Company’s capital position, legal requirements, and other factors. The repurchase program does not obligate the Company to acquire any particular number of shares, and the repurchase program may be discontinued at any time at the Company’s discretion.


Statement Regarding Forward-Looking Information


The statements contained in this release that are not historical are forward-looking statements within the meaning of the U.S. federal securities laws and we intend that such forward-looking statements be subject to the safe harbor created thereby. Statements that are not historical facts, including statements about anticipated financial outcomes, and share repurchases, as well as other statements about our expectations, beliefs, intentions, or strategies regarding the future, or other characterizations of future events or circumstances, are forward-looking statements. These statements relate to future events and our future results and involve a number of risks and uncertainties. Actual results, performance or achievement could differ materially from those contained in these forward-looking statements. Specific forward-looking statements in this press release include our Board’s confidence in our business and its dedication to stockholder value; our belief that our strong balance sheet and anticipated positive cash flow enable us to prioritize investing for growth, both organically and through opportunistic and accretive M&A activity, while maintaining our commitment to returning capital to our stockholders.  Forward-looking statements are based on our beliefs as well as assumptions made by, and information currently available to, us. The risks and uncertainties to which forward-looking statements are subject include, without limitation, changes in price and volume and the volatility of our common stock, unexpected or otherwise unplanned or alternative requirements with respect to the capital investments of the Company, changes in general economic, business and political conditions, and other risks detailed in the “Statement Regarding Forward-Looking Information,” “Risk Factors” and other sections of the Company’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Except as required by applicable law or regulation, we disclaim any obligation and do not intend to publicly update or review any of our forward-looking statements, whether as a result of new information, future events or otherwise.


About American Outdoor Brands, Inc.


American Outdoor Brands, Inc. (NASDAQ Global Select: AOUT) is an industry leading provider of outdoor products and accessories, including hunting, fishing, camping, outdoor cooking, shooting, and personal security and defense products, for rugged outdoor enthusiasts. The company produces innovative, top quality products under its brands BOG®; BUBBA®; Caldwell®; Crimson Trace®; Frankford Arsenal®; Grilla Grills®; Hooyman®; Imperial®; LaserLyte®; Lockdown®; MEAT!; Old Timer®; Schrade®; Tipton®; Uncle Henry®; ust®; and Wheeler®. For more information about all the brands and products from American Outdoor Brands, Inc., visit www.aob.com.

Contact:
Liz Sharp, VP, Investor Relations
lsharp@aob.com
(573) 303-4620

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/american-outdoor-brands-board-of-directors-approves-10-million-share-repurchase-program-301637516.html

SOURCE American Outdoor Brands, Inc.

Accuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients

PR Newswire

World’s Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out-Patient Sessions


SUNNYVALE, Calif.
, Sept. 30, 2022 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its CyberKnife® platform in Africa, making it possible for more patients to obtain access to the extremely precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments the system delivers. The Children’s Cancer Hospital 57357 (Hospital 57357) medical care team is the first in Egypt and Africa to treat patients using the system, while the Kenyatta University Teaching, Referral & Research Hospital (KUTRRH) is the second in Africa and first in Kenya to acquire the system.

The number of new cancer cases diagnosed annually in Egypt and Kenya is anticipated to increase by approximately 75% and 126%, respectively, between 2020 and 20401. Innovative treatment options – such as the CyberKnife platform – can effectively treat certain neurologic conditions and a wide range of tumor types throughout the body, and at various stages of disease, while minimizing the impact of the treatment on a patient’s life.

“Our partnerships with the Children’s Cancer Hospital 57357 and Kenyatta University Teaching, Referral & Research Hospital teams directly aligns with our vision, and their goal, to expand all patient access to the most advanced radiation therapy treatments and to improve healthcare equity in areas where historically these treatments have not been an option,” said Suzanne Winter, president and CEO of Accuray. “We are proud that such esteemed organizations have selected the CyberKnife System to enhance the quality of care they provide their patients. The system will provide them with the tools they need to offer more patients extremely precise, powerful treatments that enable them to get back to living their lives, faster.”

The entire CyberKnife procedure is typically completed in just 1 to 5 out-patient sessions, providing a shorter overall course of treatment compared to conventional radiation therapy which typically takes 30-40 sessions. The condensed treatment schedule causes less disruption of patients’ daily lives and enables those people who are unable to travel a month or more for care to receive radiation therapy treatments delivered with sub-millimeter precision and accuracy.  

Improving Patient Outcomes in Egypt
Hospital 57357 continues its legacy of innovation with the installation and treatment of the first patients in Egypt and Africa using the CyberKnife System. The radiation treatment delivered with the system is a non-invasive, non-surgical, typically pain-free outpatient procedure that does not require incisions or general anesthesia. Most patients will not require hospitalization or experience a long recovery period following the treatment procedure.

“At Children’s Cancer Hospital 57357, patients and their families are at the center of everything we do. We are proud to be the first hospital in Egypt and Africa to offer our patients treatment with the CyberKnife System, an innovative radiation therapy delivery technology we believe will enable us to improve patients’ outcomes and increase overall survival rates,” said Mohamed Saad Zaghloul, M.D., head of the radiation oncology department, Children’s Cancer Hospital 57357. “The system is designed to treat tumors throughout the body and provides us with an alternative to surgery for patients who have inoperable or surgically complex tumours, expanding the number of patients we can help.”

Dr. Zaghloul continued, “Importantly, we can decrease the number of radiation sessions needed to between 1 and 5, without sacrificing the precision of the treatment we deliver. This is a significant benefit for our patients who want to be able to get back to spending time with their families and participating in the daily activities that other children their age enjoy.”

Expanding Access to Advanced Cancer Care in Kenya
KUTRRH is a leading Public National Referral Hospital dedicated to enhancing the health and well-being of Kenyans and global citizens through provision of patient-centered and evidence-based healthcare. The CyberKnife® System will provide their team with the tools they need to provide optimal treatments for people diagnosed with cancer, benign tumors or certain neurologic disorders. The system was designed to provide clinicians with the speed required for workflow efficiency and the ability to deliver treatments more quickly – in as little as 15 minutes – while maintaining the precision and accuracy required for SRS and SBRT.

“In Kenya, cancer is a public health concern and too few people who would benefit from radiation therapy treatments are receiving care. For our region and our country, we believe the CyberKnife System will revolutionize cancer care,” said Prof. Olive Mugenda Ph.D., MGH Chairperson, Kenyatta University Teaching, Referral & Research Hospital.

Continued Prof. Mugenda, “The Cyberknife System has been one of the reason Kenyans have been travelling abroad for treatment. Having this system in Kenya, will not only improve the quality of life but also reverse outbound medical tourism.”

Jos. Hansen (East Africa) Ltd. is a leading distributor of trusted and reliable healthcare equipment and is the exclusive partner for the Accuray CyberKnife and TomoTherapy® platforms, including the next-generation Radixact® System, in Kenya. Jos. Hansen has a long-term relationship with the KUTRRH team and consulted with them as they evaluated radiation therapy devices and selected the CyberKnife S7™ System.

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company’s assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company’s ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company’s ability to develop new products or improve existing products to meet customers’ needs; the company’s ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; and such other risks identified under the heading “Risk Factors” in the company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on August 17, 2022, and as updated periodically with the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan                                                                            
Public Relations Director, Accuray                                         
+1 (408) 789-4426
[email protected]

1
https://gco.iarc.fr/tomorrow/en/dataviz/tables?populations=404_818&years=2040 

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-cyberknife-systems-in-africa-providing-a-new-option-and-hope-for-potentially-life-saving-radiation-treatments-for-more-cancer-patients-301637437.html

SOURCE Accuray Incorporated

Westport Announces the Resignation of Chief Financial Officer Richard Orazietti and Appoints William Larkin as Successor

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport” or the “Company”) (TSX: WPRT / Nasdaq: WPRT) today announced the resignation of its Chief Financial Officer (CFO), Richard Orazietti, for personal reasons. Mr. Orazietti will continue in his capacity as CFO until November 30, 2022, following the release of Westport’s third quarter 2022 results, to ensure a smooth transition and the seamless transfer of duties and responsibilities.

“On behalf of myself and the Board, I would like to thank Richard for his commitment and significant contributions to Westport,” said David Johnson, Chief Executive Officer of Westport. “Since joining in 2019, Richard led Westport through a critical period and has positioned us for long-term success by strengthening our financial position. Richard has been a valuable member of our management team, and we wish him well in the future,” he added.

“I am proud of how our team successfully refinanced Westport providing a solid balance sheet to expand and drive growth with the continued development of our revolutionary H2 HPDI™ fuel system despite many headwinds during my tenure,” said Richard Orazietti. “I would like to thank my team for their efforts in the ongoing initiatives to enhance risk management and compliance processes and further building on the foundations of a strong finance function. My resignation was a difficult decision for me, but I have the utmost confidence in the future of Westport and would like to sincerely thank the Board and David for the opportunity to serve as CFO, with a talented group of colleagues, in a sector I truly believe in.”

Succeeding Richard Orazietti is William Larkin, a seasoned finance executive with more than fourteen years in the CFO role in both public and private companies. His experiences span a diverse set of corporate environments ranging from entrepreneurial start-ups, high growth small caps and mature enterprises across various industries focusing on corporate development, finance, and strategy. Most recently, he served as CFO of Akumin, Inc. He is returning to Westport having served as CFO of Westport Fuel Systems Inc. (then known as Westport Innovations Inc.) from 2010 through 2014, and he also served in progressively senior positions at Fuel Systems Solutions, Inc., including CFO. Mr. Larkin began his career as a Certified Public Accountant with Deloitte & Touche and is a veteran of the US Army; he has a Bachelor of Science degree in accounting from the University of Southern California.

“Bill is a well-respected and experienced finance leader, and we look forward to welcoming him back to the Westport team,” continued David Johnson. “The deep industry experience and capabilities that he brings will be instrumental in Westport realizing our growth and profitability goals.”

William Larkin joins Westport in October 2022 and will work closely with Richard Orazietti to ensure a smooth transition.

About Westport Fuel Systems

At Westport Fuel Systems, we are driving innovation to power a cleaner tomorrow. We are a leading supplier of advanced fuel delivery components and systems for clean, low-carbon fuels such as natural gas, renewable natural gas, propane, and hydrogen to the global automotive industry. Our technology delivers the performance and fuel efficiency required by transportation applications and the environmental benefits that address climate change and urban air quality challenges. Headquartered in Vancouver, Canada, with operations in Europe, Asia, North America, and South America, we serve our customers in more than 70 countries with leading global transportation brands. At Westport Fuel Systems, we think ahead. For more information, visit www.wfsinc.com.

For more information contact:

Investor Relations
T: +1 604-718-2046
E:[email protected]

Media Relations
T: +1 947-339-8097
E:[email protected]



Oragenics Issues Letter to Shareholders

Oragenics Issues Letter to Shareholders

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy.

To My Fellow Shareholders,

As COVID-19 continues to impact the world’s population – albeit with far less dire consequences due to the availability of vaccines, therapeutics and better in-hospital care of those with severe disease – a sense of normalcy has returned to daily life. Nonetheless, the persistence of the SARS-CoV-2 virus and its more contagious variants continue to present major global challenges and widespread death. Yet we have become much smarter in our battle against the virus, innovating more durable protection and better controlling transmission.

Perhaps most importantly, we have learned that the best protection against infection with SARS-CoV-2 is achieved by targeting the site of virus transmission, the upper respiratory tract and mouth, which is the focus of Oragenics’ ongoing research and development.

We remain confident in our strategic direction and specifically in our plans to advance NT-CoV2-1, our lead intranasal vaccine candidate, into human clinical trials in the first half of 2023. In this letter, I’d like to provide an overview of why I see NT-CoV2-1 as an important component in overcoming this global challenge, and review the current status of our work and next steps.

Benefits & Mechanism of Intranasal Vaccines

As most of you know, in late June I took over the day-to-day leadership of Oragenics from Fred Telling, and we are fortunate that Fred remains a Director of our company. Although I’m new to the CEO role, I’m not new to Oragenics as I have served on the Company’s Board of Directors since 2020.

Bringing to my new role more than 25 years of experience in vaccine development, I’m so very proud of the preclinical work the Oragenics team has conducted so far. Collectively we have evaluated various adjuvants and determined that BDX301 provides the optimal path forward by targeting the mucosal immunity that protects against initial infection. Although our preclinical results support development in either the intramuscular or the intranasal route of administration, we believe intranasal delivery holds multiple relative and absolute benefits and, as such, this is the route we are taking which also aligns with industrywide trends in vaccine development.

More specifically, the benefits associated with the intranasal delivery of NT-CoV2-1 include:

  • Meaningful differentiation for children and needle-phobic adult populations
  • Potential for single-dose efficacy along with enhanced durability
  • Significantly easier storage and transport requirements
  • The targeting of mucosal immunity

With regard to mucosal immunity, conventional injectable vaccines are poor inducers of mucosal immunity, whereas intranasal immunization can induce strong mucosal immunity by enhancing the immune response at the entry sites of mucosal pathogens. When the SARS-CoV-2 virus enters the nasal cavity, the respiratory epithelial layer is the body’s first barrier against viral infection.

In fact, the intranasal route of vaccination provides two additional layers of protection over intramuscular shots because it produces immunoglobulin A and resident memory B and T cells in the respiratory mucosa that are an effective barrier to infection at those sites. Additionally, cross-reactive resident memory B and T cells can respond earlier than other immune cells should a viral variant start an infection, providing needed durability against evolving variants.

Further Advantages to Our Vaccine Development Approach

Oragenics’ NT-CoV2-1 program leverages coronavirus spike protein research that we licensed from the National Institutes of Health (NIH) and a Chinese hamster ovary cell line expression system licensed from the National Research Council of Canada (NRC).

Our program holds potential for faster development of spike protein antigens, or immune system response stimulants, to address new SARS-CoV-2 variants as they emerge. In addition, our platform may allow for the production of cell lines within six to eight weeks after receiving spike gene sequence information, which is far faster than the six to nine months typically required for traditional production of such cell lines.

Favorable Preclinical Profile

This past June we announced the publication of an article co-authored by Oragenics and our collaborators at Inspirevax and the NRC’s Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.

The article reported that the intranasal formulation induced robust antigen-specific IgG and IgA titers in the blood and lungs of mice and was highly efficacious in a hamster challenge model, reducing the viral load below the limit of detection. In both mice and hamsters, the antibodies had strong neutralizing activity, preventing the cellular binding of the viral spike protein based on the ancestral SARS-CoV-2 reference strain and certain variants of concern.

These encouraging conclusions enabled us to initiate the currently ongoing toxicology study, which is focused exclusively on the intranasal route of administration.

Status of Our Toxicology Study

The pivotal preclinical Good Laboratory Practice (GLP) toxicology study is evaluating the safety and immunogenicity of NT-CoV2-1 in rabbits, and we expect it to conclude by the end of this year. In late August we announced preliminary results that continued to demonstrate a safety profile and immune responses that we believe will support regulatory filings to progress to a Phase 1 clinical study, which is a very encouraging checkpoint as we approach the conclusion of the study.

The objectives of this study are to evaluate the potential toxicity of NT-CoV2-1 following repeated intranasal administration at the maximum dose anticipated to be used in human trials, and to confirm the immunogenicity of the vaccine. The only remaining portion of the toxicology report is completion of the ongoing histopathology evaluation, after which Oragenics will package the results into a regulatory application for approval to begin clinical trials.

Regulatory Next Steps

Given Health Canada’s experience with the proteasome-based mucosal adjuvant BDX301 and the growing urgency for intranasal vaccines, our optimal path forward is to submit a Clinical Trial Application (CTA) with Health Canada following the completion of the GLP toxicology study. We currently expect to make that submission by early 2023, once the full histopathology report is in hand.

Oragenics is working to expedite the path to market for NT-CoV2-1 and we have optionality with a dual path in both Canada and the U.S. for the necessary Investigational New Drug (IND)-enabling work. Following CTA submission and approval, Oragenics will commence clinical studies in Canada while evaluating the potential for launching parallel studies in the U.S. We currently envision the start of clinical studies in Canada in the first half of next year.

Looking Forward

Our focus remains on developing NT-CoV2-1 as a single-dose booster in the pandemic and endemic phases of the COVID-19 health crisis, and this focus is informed by the evolving market opportunity for COVID-19 vaccines. The market for booster doses is where we expect to position NT-CoV2-1 to compete, and that market will be driven by the need for updated vaccines to provide protection against future variants of the SARS-CoV-2 virus, as well as by the need to vaccinate infants and children.

On behalf of the Oragenics team, as well as our Board of Directors, I want to thank our stockholders for their continued support and I look forward to keeping you updated on our progress as we advance toward a durable solution to the COVID-19 pandemic.

Sincerely,

Kim Murphy

President and Chief Executive Officer

September 30, 2022

About Oragenics

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: the Company’s ability to advance the development of its vaccine candidate and lantibiotics candidate under the timelines and in accord with the milestones it projects; the Company’s ability to obtain funding, non-dilutive or otherwise, for the development of the vaccine and lantibiotic product candidates, whether through its own cash on hand, or another alternative source; the regulatory application process, research and development stages, and future clinical data and analysis relating to vaccines and lantibiotics, including any meetings, decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable; the potential application of our vaccine candidate to variants and other coronaviruses; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments and demand for vaccines and antibiotics; the Company’s expectations as to the outcome of preclinical studies, nasal administration, transmission, manufacturing, storage and distribution; other potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, interruptions to manufacturers and supply chains, adverse impacts on healthcare systems and disruption of the global economy; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

Oragenics, Inc.

Michael Sullivan, Chief Financial Officer

813-286-7900

[email protected]

LHA Investor Relations

Tirth T. Patel

212-201-6614

[email protected]

KEYWORDS: Florida United States North America Canada

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Health COVID-19 Infectious Diseases Clinical Trials

MEDIA:

Logo
Logo

Chicago Faith Leaders Plan Coordinated Sermons to Destigmatize Mental Health in Underserved Communities

Chicago Faith Leaders Plan Coordinated Sermons to Destigmatize Mental Health in Underserved Communities

More than 80 pastors aim to reach congregants in Oct. 9 sermons in honor of World Mental Health Day

CHICAGO–(BUSINESS WIRE)–
Faith leaders from more than 80 Black churches in Chicago met on September 29, 2022, to discuss mental health stigma and learn how to better minister to mental health concerns among their congregants. The forum, which also featured local leaders in health care, community activism, and government, was held to educate and empower the attending faith leaders to open up conversations about mental health with congregants on Oct. 9 in honor of World Mental Health Day.

Donald Dew, President and CEO of Habilitative Systems, Inc., Dr. Obari Cartman, President of Chicago Association of Black Psychologists, and Adrienne McCue, President and Executive Director of Step Up for Mental Health, took part in a panel discussion that was moderated by Dennis Deer, Cook County Board Commissioner, and convened and coordinated by Evolent Health.

On Oct. 9, one day before World Mental Health Day, congregants will hear from pastors and faith leaders about the importance of mental health as a part of overall health. Sermons and homilies will share guidance on facilitating discussions with loved ones and directing them to appropriate resources and care.

“Last year, Cook County declared mental health and lack of mental health services a public health crisis. This issue has been exacerbated by the pandemic. Mental health concerns are as important and urgent as physical health concerns,” said Commissioner Deer. “It’s time to destigmatize seeking treatment, open more funding and access to mental health care and encourage people to seek resources and pathways to care. It’s our job as community leaders to help them open that door.”

Mental health clinicians in Chicago are not equitably available. Deer notes that the most affluent neighborhoods in his district have 5 mental health clinicians for every 100 people. On the west side and less affluent parts of his district, it’s just one clinician for every 1,000 people.

“We have to change the way we think about how we access mental health care, and we need more support and funding in the area of behavioral health,” said Apostle Carl L. White, Jr., Sr. Pastor, Victory Christian International Ministries in Harvey, Ill., and CEO, Southland Ministerial Health Network, “But lacking those resources right now, we must take action ourselves. We’re calling on congregants to create safe spaces for their families and friends, asking them to give themselves the grace to ask for and accept support, and sharing resources for them to increase awareness of and access to that support.”

Evolent Health, a health care managed services company supporting the care of more than 435,000 Medicaid beneficiaries in Cook County, convened the group and has been collaborating with them on promoting mental health awareness in Chicago since August of 2022.

“It takes 11 years on average between someone initially experiencing mental health symptoms, and that person getting treatment,” said Naprisha Taylor, Vice President, Office of the CEO and Diversity, Equity and Inclusion at Evolent. “We all know this is too long, and we want to see more people receiving the support they need sooner. We at Evolent are honored to be a part of mobilizing the Chicago community and encouraging healthy and productive discussions to close the care gap.”

About Evolent Health

Evolent Health (NYSE: EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance’s Population Health Program Accreditation and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

Kelly McIntosh

The Bliss Group

336.543.3065

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: State/Local Public Policy Insurance Healthcare Reform Pharmaceutical Managed Care Professional Services Mental Health Seniors Religion Public Policy/Government Family Science Other Science Consumer Health

MEDIA:

Logo
Logo